Loading
A phase 2 trial of Docetaxel in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors is a phase 2 interventional study registered as NCT05631262 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 321 participants enrolled, started 2022-11-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: SKB264 and Docetaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Docetaxel, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/